FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from autologous stem cell transplantation international scleroderma trial. PMID 41372962 · Arthritis Res Ther · 2025-Dec-10 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| First-line medical thoracoscopy for pleural infection: the SPIRIT randomised controlled feasibility trial. PMID 41371905 · BMJ Open Respir Res · 2025-Dec-10 The study is excluded because it is not oncology-related, lacks a drug intervention, is a feasibility study (not Phase III), and does not report time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis. PMID 41371743 · BMJ Open · 2025-Dec-10 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial. PMID 41366419 · Trials · 2025-Dec-10 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The impact of discontinuation and non-publishing of osteoporosis clinical trials. PMID 41364747 · J Osteopath Med · 2025-Dec-10 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical Significance of Intratumoral Contrast Pooling on Contrast-Enhanced CT After Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma. PMID 41440222 · Curr Oncol · 2025-Dec-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study). PMID 41240533 · Eur J Cancer · 2025-Dec-09 The study is an original Phase III randomized trial with a drug intervention (letrozole) and is oncology-focused in humans. However, the primary endpoint is incidence (5-year incidence of invasive BC), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) requiring Kaplan-Meier or HR for survival/disease progression. The hazard ratio provided is for incidence, not a standard time-to-event outcome. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial. PMID 41207182 · Eur J Cancer · 2025-Dec-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis. PMID 41197289 · Eur J Cancer · 2025-Dec-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer. PMID 41192233 · Eur J Cancer · 2025-Dec-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Can NaCl predict or even enhance responses to immunotherapy in cancer? PMID 41138602 · Eur J Cancer · 2025-Dec-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of tranexamic acid on postpartum hemorrhage in type 1 von Willebrand disease treated with recombinant VWF. PMID 40902088 · Blood Adv · 2025-Dec-09 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial. PMID 40892606 · J Am Coll Cardiol · 2025-Dec-09 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma. PMID 40829107 · Blood Adv · 2025-Dec-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the 'MOI-A' study; a randomised, phase 2/pilot, dose-escalating trial. PMID 41360460 · BMJ Open · 2025-Dec-07 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. PMID 41354932 · J Hematol Oncol · 2025-Dec-07 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial. PMID 41354738 · Nat Commun · 2025-Dec-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Hydroxychloroquine does not affect endotheliopathy or coagulopathy biomarkers in COVID-19: longitudinal results from the DisCoVeRy randomized trial. PMID 41353681 · Angiogenesis · 2025-Dec-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
L
|
旧查询独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Body and Mind Programme for recovery from breast cancer: Evaluation of the impact of health promotion intervention carried out in a multidisciplinary team on health-promoting behaviours: a quasi-randomised-controlled clinical trial. PMID 41353158 · BMC Psychol · 2025-Dec-07 The study is a quasi-randomized controlled trial evaluating a non-drug health promotion intervention for breast cancer patients. It lacks a drug intervention and a primary time-to-event efficacy endpoint, and the phase is not established as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup-Combined Efficacy and Safety Analysis from SPOTLIGHT and GLOW. PMID 41381060 · Cancer Res Treat · 2025-Dec-05 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
S
B
|
严格 v3 独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer. PMID 41360427 · J Immunother Cancer · 2025-Dec-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparison of laparoscopic and open stand-alone feeding jejunostomy in patients with proximal gastrointestinal tract malignancies: An open-label randomised controlled trial. PMID 41351262 · J Minim Access Surg · 2025-Dec-05 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Expanding insights from the VISTA phase III trial: longitudinal comparative assessment of ellipsoid zone integrity and volumetric fluid dynamics. PMID 41350590 · Sci Rep · 2025-Dec-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn's disease. PMID 41258994 · J Crohns Colitis · 2025-Dec-05 The record is from a Phase III randomized trial with a drug intervention and original results, but it is excluded because the condition (Crohn's disease) is not oncology, and the study does not have a primary/key time-to-event efficacy endpoint as required. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tolerability, safety, and preliminary immunogenicity assessment of different dosages of Quadrivalent inactivated influenza vaccine in healthy subjects aged 6-35 months: A single-center, dose-escalation, open-label phase I clinical trial. PMID 41207071 · Vaccine · 2025-Dec-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants. PMID 41187484 · Vaccine · 2025-Dec-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Endoscopic or surgical gastroenterostomy for malignant gastric outlet obstruction: a randomised trial. PMID 40998416 · Gut · 2025-Dec-05 The trial is a randomized, multicenter study in patients with malignant gastric outlet obstruction, which is oncology-related. It reports primary results of a randomized comparison. However, it is excluded because the intervention (endoscopic vs. surgical gastroenterostomy) is not a drug-containing intervention, and the primary endpoint is a composite clinical outcome measure, not a time-to-event efficacy endpoint like overall survival or progression-free survival. No Kaplan-Meier curves or hazard ratios are mentioned. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications. PMID 41462987 · Biomedicines · 2025-Dec-04 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Surveillance After Extremity Tumor Surgery (SAFETY) Pilot International Multi-Center Randomized Controlled Trial. PMID 41440214 · Curr Oncol · 2025-Dec-04 This is an oncology, human, randomized pilot trial evaluating a non-drug intervention (surveillance frequency and imaging modality) for soft-tissue sarcoma. It lacks a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The report describes feasibility and aggregate outcomes, not a definitive Phase III/IIIb trial with a drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON). PMID 41345848 · BMC Pulm Med · 2025-Dec-04 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparison of the effect on treatment satisfaction of switching from multiple insulin injection therapy to additional administration of imeglimin in subjects with type 2 diabetes (MEGMI-TS): study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison trial. PMID 41345697 · Trials · 2025-Dec-04 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| PERi-operative Selective Decontamination of the digestive tract to prevent severe infectious complications after Esophageal Resection: study protocol of the PERSuaDER-trial, a multicenter randomized controlled trial in patients with primary resectable esophageal carcinoma. PMID 41345690 · Trials · 2025-Dec-04 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Loberamisal for Acute Ischaemic Stroke (LAIS): a multicentre, randomised, double-blind, parallel, placebo-controlled phase III clinical trial. PMID 41344725 · Stroke Vasc Neurol · 2025-Dec-04 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Implementation evaluation of an evidence-informed hospital inpatient nursing framework (HIRAID® Inpatient): a protocol for a stepped-wedge cluster RCT. PMID 41339957 · Trials · 2025-Dec-04 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. PMID 41337715 · N Engl J Med · 2025-Dec-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial. PMID 40939190 · Blood · 2025-Dec-04 The record describes a Phase III trial with drug interventions and time-to-event endpoints, but it lacks explicit evidence of randomization (the abstract describes comparing outcomes based on different regimens chosen by local practice, not randomized assignment). Therefore, the required criterion of randomization is not met. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of short-term outcomes and oncological outcomes between totally laparoscopic distal gastrectomy and pylorus-preserving gastrectomy for early gastric cancer in the middle stomach: a non-inferiority randomised controlled trial. PMID 41482811 · Int J Surg · 2025-Dec-03 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Research waste among randomized clinical trials in endoscopic resection of gastrointestinal lesions: a cross-sectional study of ClinicalTrials.gov. PMID 41340094 · BMC Gastroenterol · 2025-Dec-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial. PMID 41339350 · Nat Commun · 2025-Dec-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Chemical Optimization of Cerebral Embolectomy 2 (CHOICE 2) trial: study protocol. PMID 41339082 · Stroke Vasc Neurol · 2025-Dec-03 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic versus open distal gastrectomy with D2 lymphadenectomy following neoadjuvant chemotherapy for locally advanced gastric cancer (CLASS-03b): protocol for a multicentre, randomised, controlled, non-inferiority trial. PMID 41338637 · BMJ Open · 2025-Dec-03 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Transtympanic sodium thiosulphate to prevent cisplatin-related hearing loss: a protocol for randomised controlled multicentre phase III trial, the SOUND trial. PMID 41338634 · BMJ Open · 2025-Dec-03 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effect of the index of consciousness 2 on intraoperative opioid dosage in ovarian cancer patients receiving neoadjuvant chemotherapy: a study protocol for a randomised controlled trial. PMID 41338618 · BMJ Open · 2025-Dec-03 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Comparison of the EndoGIA versus the Endowrist stapler in intracorporeal urinary diversion in robotic assisted radical cystectomy (EGIAES) - a randomized multicentre trial. PMID 41335393 · J Robot Surg · 2025-Dec-03 The study is a randomized controlled trial in oncology (bladder cancer) with a primary efficacy endpoint, but the intervention is a comparison of surgical stapler devices (non-drug-only), and the primary endpoint (time to first flatus/bowel movement, POI rate, LOS) is not a time-to-event efficacy endpoint as defined (OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU). PMID 41331921 · BMC Cancer · 2025-Dec-03 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Impact of Anthelmintic Therapy for Invasive Helminth Infection on Microbial Translocation, Inflammation, and Immune Response among Ugandans Living with HIV: A Randomized Proof of Concept Study. PMID 41130223 · Am J Trop Med Hyg · 2025-Dec-03 The study is a randomized proof-of-concept trial evaluating anthelmintic therapy for helminth infection in people living with HIV. It is not a study of a human malignant neoplasm (cancer). Therefore, it does not meet the primary inclusion criterion of being an oncology study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma. PMID 40891733 · Jpn J Clin Oncol · 2025-Dec-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The outcome of injured cervical spinal cord with uncontrolled swelling under duraplasty: protocol of the ISCUD randomized controlled trial. PMID 41331929 · Trials · 2025-Dec-02 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of autologous adipose-derived stem cells in subjects with moderate to severe atopic dermatitis: a multicenter, randomized, single-blind, placebo-controlled, phase 2 trial. PMID 41331725 · Stem Cell Res Ther · 2025-Dec-02 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of Health Education on Cervical Cancer Screening Uptake and Knowledge among Target Women in Addis Ababa: A Randomized Controlled Trial. PMID 40878788 · Cancer Prev Res (Phila) · 2025-Dec-02 The study is a randomized controlled trial in oncology (cervical cancer prevention), but it is excluded because it lacks a drug-containing intervention (it uses health education), does not report a time-to-event efficacy endpoint (primary outcome is screening uptake proportion), and is not a definitive Phase III/IIIb trial (phase not specified). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |